226 related articles for article (PubMed ID: 22142585)
1. Selection and characterization of vaccine strain for Enterovirus 71 vaccine development.
Chang JY; Chang CP; Tsai HH; Lee CD; Lian WC; Ih-Jen-Su ; Sai IH; Liu CC; Chou AH; Lu YJ; Chen CY; Lee PH; Chiang JR; Chong PC
Vaccine; 2012 Jan; 30(4):703-11. PubMed ID: 22142585
[TBL] [Abstract][Full Text] [Related]
2. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates.
Chou AH; Liu CC; Chang CP; Guo MS; Hsieh SY; Yang WH; Chao HJ; Wu CL; Huang JL; Lee MS; Hu AY; Lin SC; Huang YY; Hu MH; Chow YH; Chiang JR; Chang JY; Chong P
PLoS One; 2012; 7(4):e34834. PubMed ID: 22529942
[TBL] [Abstract][Full Text] [Related]
3. Production of EV71 vaccine candidates.
Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
[TBL] [Abstract][Full Text] [Related]
4. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
Li J; Liu G; Liu X; Yang J; Chang J; Zhang W; Yu XF
Viruses; 2015 Jul; 7(7):3891-909. PubMed ID: 26193302
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
6. Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model.
Hankaniemi MM; Laitinen OH; Stone VM; Sioofy-Khojine A; Määttä JAE; Larsson PG; Marjomäki V; Hyöty H; Flodström-Tullberg M; Hytönen VP
Vaccine; 2017 Jun; 35(30):3718-3725. PubMed ID: 28579231
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-growth enterovirus 71 vaccine candidate inducing cross-reactive neutralizing antibody responses.
Chia MY; Chung WY; Wang CH; Chang WH; Lee MS
Vaccine; 2018 Feb; 36(9):1167-1173. PubMed ID: 29398272
[TBL] [Abstract][Full Text] [Related]
8. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.
Wu CY; Lin YW; Kuo CH; Liu WH; Tai HF; Pan CH; Chen YT; Hsiao PW; Chan CH; Chang CC; Liu CC; Chow YH; Chen JR
PLoS One; 2015; 10(8):e0136420. PubMed ID: 26287531
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
10. Inactivated enterovirus 71 with poly-γ-glutamic acid/Chitosan nano particles (PC NPs) induces high cellular and humoral immune responses in BALB/c mice.
Pathinayake PS; Gayan Chathuranga WA; Lee HC; Chowdhury MYE; Sung MH; Lee JS; Kim CJ
Arch Virol; 2018 Aug; 163(8):2073-2083. PubMed ID: 29619599
[TBL] [Abstract][Full Text] [Related]
11. Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine.
Wang KT; Lin SJ; Wang HC; Chen PC; Lin JJ; Chiang JR; Chang CL; Shih DY; Lo CF; Wang DY
Biologicals; 2016 Jul; 44(4):183-190. PubMed ID: 27068365
[TBL] [Abstract][Full Text] [Related]
12. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys.
Dong C; Wang J; Liu L; Zhao H; Shi H; Zhang Y; Jiang L; Li Q
Hum Vaccin; 2010 Dec; 6(12):1028-37. PubMed ID: 21150270
[TBL] [Abstract][Full Text] [Related]
13. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice.
In HJ; Lim H; Lee JA; Kim HJ; Kim JW; Hyeon JY; Yeo SG; Lee JW; Yoo JS; Choi YK; Lee SW
PLoS One; 2017; 12(5):e0178259. PubMed ID: 28542556
[TBL] [Abstract][Full Text] [Related]
14. Structure, Immunogenicity, and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
Wang X; Ku Z; Zhang X; Ye X; Chen J; Liu Q; Zhang W; Zhang C; Fu Z; Jin X; Cong Y; Huang Z
J Virol; 2018 Jan; 92(1):. PubMed ID: 29070691
[TBL] [Abstract][Full Text] [Related]
15. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles.
Lin YL; Yu CI; Hu YC; Tsai TJ; Kuo YC; Chi WK; Lin AN; Chiang BL
Vaccine; 2012 Feb; 30(7):1305-12. PubMed ID: 22214888
[TBL] [Abstract][Full Text] [Related]
16. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine.
Han X; Ying XL; Zhou SL; Han T; Huang H; Jin Q; Yang F; Sun QY; Sun XX
Hum Vaccin Immunother; 2014; 10(8):2220-6. PubMed ID: 25424925
[TBL] [Abstract][Full Text] [Related]
18. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the enterovirus 71 VP1 protein as a vaccine candidate.
Zhou SL; Ying XL; Han X; Sun XX; Jin Q; Yang F
J Med Virol; 2015 Feb; 87(2):256-62. PubMed ID: 25043151
[TBL] [Abstract][Full Text] [Related]
20. Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys.
In HJ; Lim H; Lee JA; Lee SR; Jin YB; Jeong KJ; Hyeon JY; Yoo JS; Lee JW; Choi YK; Lee SW
PLoS One; 2018; 13(10):e0202552. PubMed ID: 30278051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
